Study To Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of an Anti-CTLA-4 Human Monoclonal Antibody (AGEN1884), and to Estimate the Maximum Tolerated Dose in Subjects With Advanced or Refractory Cancer

Trial Profile

Study To Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of an Anti-CTLA-4 Human Monoclonal Antibody (AGEN1884), and to Estimate the Maximum Tolerated Dose in Subjects With Advanced or Refractory Cancer

Recruiting
Phase of Trial: Phase I

Latest Information Update: 07 Nov 2017

At a glance

  • Drugs AGEN 1884 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Agenus
  • Most Recent Events

    • 07 Nov 2017 According to an Agenus media release, the company anticipates to complete dose-escalation and compile safety and pharmacodynamic data in 4Q 2017.
    • 03 Aug 2017 According to an Agenus media release, the company anticipates to complete dose-escalation and compile safety and pharmacodynamic data in the second half of 2017.
    • 06 Jun 2017 Results (n=11) presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top